In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may ...

William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...

The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 ...

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...

Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval ...

UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a potential treatment for ...

A common heart drug has shown promise to delay the onset of Huntington's disease -- a progressive and inherited brain ...